Tarsus Pharmaceuticals (TARS)
(Delayed Data from NSDQ)
$34.51 USD
-0.09 (-0.26%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $34.46 -0.05 (-0.14%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Tarsus Pharmaceuticals, Inc. [TARS]
Reports for Purchase
Showing records 1 - 15 ( 15 total )
Company: Tarsus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
1Q24: Another Quarter, Another Big XDEMVY Beat; Raise PT to $61
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Tarsus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
4Q23: XDEMVY Trouncing Early Expectations; Raise to $57
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Tarsus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
GAVRETO Joins Rigel''s Roster of Marketed Drugs Following Asset Acquisition
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Tarsus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for TARS 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: Tarsus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q23: XDEMVY Launching Ahead of Our Projections; Raise PT to $50
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Tarsus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2Q23: XDEMVY Launch Commencing End of Month; Early Stage Lotilaner Pipeline Readouts Before Year-End; PT to $42
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Tarsus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Early XDEMVY (TP-03) Approval; Ready to Launch Into Unserved Large DB Indication; Raise to $50
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Tarsus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Commercial Strategy Update Signals Optimism Ahead of August 25 TP-03 PDUFA; Raise PT to $44 on Product Pricing
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Tarsus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Ramping Toward TP-03 August PDUFA Date; See Stock Undervaluing Potential in DB; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Tarsus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
TP-03 Demodex Blepharitis NDA Filed On Schedule; Lotilaner Pipeline Progressing in Parallel; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Tarsus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Saturn-2 Hits All Endpoints; Unequivocally Positive Efficacy, in Our View; Weakness Unwarranted; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Tarsus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
4Q: Pivotal TP-03 Data by Late-April Then 2H NDA Filing, Earlier Lotilaner Pipeline (Upside) Advancing
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Tarsus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Second TP-03 DB Pivotal Fully Enrolled; Expect Positive Results by End-April and 2H Filing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Tarsus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
We initiate coverage of Tarsus Pharmaceuticals with a Buy rating
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Tarsus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
|